Wave Life Sciences Ltd Expected To Post A Loss Of 21 Cents A Share: Earnings Preview

Wave Life Sciences

29/04/2024 13:58

* WAVE Life Sciences Ltd  WVE.OQ   WVE.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 1
(estimated) for the period ending March 31 2024
    * The  Singapore-based   company is expected to report a
77.5% increase in revenue to $22.946 million from $12.93 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for WAVE Life Sciences Ltd
is for
a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for WAVE Life
Sciences Ltd is $13.50​, above​ its last closing price of $4.66.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.13       -0.23      -0.15     Beat    33.8
 Sep. 30 2023  -0.11       -0.18      0.07      Beat    139.3
 Jun. 30 2023  -0.32       -0.33      -0.20     Beat    39.7​
 Jan. 1 0001   -0.17       -0.04      -0.27     Missed  -575
 ​​Jan.        -0.47       -0.41      -0.47     Missed  -14.6
 1 0001                                                 
 Sep. 30 2022  -0.50       -0.50      -0.42     Beat    15.4​
 Jun. 30 2022  -0.54       -0.54      -0.62     Missed  -14
 Mar. 31 2022  -0.55       -0.55      -0.62     Missed  -11.7
 This summary was machine generated April 29 at 12:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)